Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "A Rosenthal" Clear advanced filters

  • In a study published in The Lancet, long-term androgen suppression (AS) combined with radiotherapy, compared with AS alone, improved outcomes in patients with locally advanced but nonmetastatic prostate cancer. The combined therapy significantly reduced prostate-cancer-specific deaths at 10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.

    • Seth A. Rosenthal
    News & Views
    Nature Reviews Urology
    Volume: 6, P: 250-251

  • Multimodal treatment utilizing combined androgen suppression and radiotherapy has improved survival rates for patients with high-risk prostate cancer. Rosenthal and Sandler provide a timely summary of the clinical trials that have been carried out in this area, as well as discussing recent advances in dose-escalated radiotherapy and adjuvant chemotherapy.

    • Seth A. Rosenthal
    • Howard M. Sandler
    Reviews
    Nature Reviews Urology
    Volume: 7, P: 31-38